914660-36-9

Basic information

• Product Name: (4-(4-CHLOROPHENYL)(2,5-THIAZOLYL))(4-(TRIFLUOROMETHOXY)PHENYL)AMINE
• Synonyms: (4-(4-CHLOROPHENYL)(2,5-THIAZOLYL))(4-(TRIFLUOROMETHOXY)PHENYL)AMINE
• CAS NO: 914660-36-9
• Molecular Formula: C16H10ClF3N2OS
• Molecular Weight: 370.78
• Mol File: 914660-36-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-(4-CHLOROPHENYL)(2,5-THIAZOLYL))(4-(TRIFLUOROMETHOXY)PHENYL)AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(4-CHLOROPHENYL)(2,5-THIAZOLYL))(4-(TRIFLUOROMETHOXY)PHENYL)AMINE(914660-36-9)
• EPA Substance Registry System: (4-(4-CHLOROPHENYL)(2,5-THIAZOLYL))(4-(TRIFLUOROMETHOXY)PHENYL)AMINE(914660-36-9)

Safety Data

• Hazardous Substances Data: 914660-36-9(Hazardous Substances Data)

Upstream product

• 142229-74-1 N-<4-(trifluoromethoxy)phenyl>thiourea 
• 536-38-9 4-chlorobenzoylmethyl bromide 
• 163490-80-0 N-(4-(trifluoromethoxy)phenylcarbamothioyl)benzamide 
• 99-91-2 para-chloroacetophenone 

Relevant articles and documents

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2-yl)-(2,4′-bithiazol)-2′-amine (24, ST-1803; IC50values: 7.3 μM (SphK1), 6.5 μM (SphK2)) as a promising candidate for further in vivo investigations and structural development.

THIAZOLE COMPOUNDS AND METHODS OF USE

The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/ or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.